Grifols (GRFS) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $6.60B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | ES | CEO | Jose Ignacio Abia Buenache |
| IPO Date | 2011-06-02 | CAGR | 14.02% |
| Employees | 25,258 | Website | www.grifols.com |
| Div. Yield | 1.09% | Payout Ratio | 28% |
| Buy Back Yield | — | Total Yield | 1.09% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $12.04B | P/E | 8.96 | Forward P/E | 5.41 | PEG | 0.31 |
| P/S | 0.68 | P/B | 0.92 | P/CF | 4.69 | P/FCF | 6.69 |
| Sales | $8.58B | Sales 1Y | -0.21% | Sales 3Y | 15.02% | Sales 5Y | 32.21% |
| EPS | $0.87 | EPS 1Y | 54.41% | EPS 3Y | 393.37% | EPS 5Y | -36.07% |
| Sales QoQ | 8.45% | EPS QoQ | 109.09% | Sales QoQ Avg | 0.09% | EPS QoQ Avg | 18.28% |
| Gross Margin | 37.23% | Operating Margin | 16.66% | Profit Margin | 6.09% | ROCE | 6.93% |
| ROA | 2% | ROE | 8% | Altman Z Score | 1.06 | Piotroski Score | 7 |
| Current Ratio | 2.37 | Quick Ratio | 0.81 | Cash Ratio | 0.23 | Op. CF Ratio | 0.1 |
| Debt/Equity | 1.54 | Debt/Assets | 0.42 | Lt Debt/Equity | 1.46 | Lt Debt/Cap. | 0.56 |
| Intrst Cov. | 2.31 | Inventory Turnover | 1.33 | Asset Turnover | 0.37 | Receivables Turnover | 6.24 |
| Enterprise Value | $12.04B | P/E Ratio | 8.96 |
| Forward P/E | 5.41 | PEG Ratio | 0.31 |
| P/S Ratio | 0.68 | P/B Ratio | 0.92 |
| P/CF Ratio | 4.69 | P/FCF Ratio | 6.69 |
| EPS | $0.87 | EPS Growth 1Y | 54.41% |
| EPS Growth 3Y | 393.37% | EPS Growth 5Y | -36.07% |
| Revenue Growth 1Y | -0.21% | Gross Margin | 0.37% |
| Operating Margin | 0.17% | Profit Margin | 0.06% |
| ROE | 0.08% | ROA | 0.02% |
| ROCE | 0.07% | Current Ratio | 2.37 |
| Quick Ratio | 0.81 | Cash Ratio | 0.23 |
| Debt/Equity | 1.54 | Interest Coverage | 2.31 |
| Altman Z Score | 1.06 | Piotroski Score | 7 |
Grifols (GRFS) valuation & financials
Grifols (GRFS) has a market capitalization of $6.60B and trades at a price-to-earnings ratio of 9.0. It operates in the Healthcare sector (Drug Manufacturers - General).
Grifols's revenue grew -0.2% over the last year.
Grifols's next earnings report is scheduled for November 10, 2026; analysts estimate EPS of $0.30. Check the earnings calendar to see all companies reporting this week.
Grifols (GRFS) — frequently asked questions
When does Grifols (GRFS) report earnings next?
Grifols is expected to report earnings on November 10, 2026. Analysts estimate EPS of $0.30.
What is Grifols's market cap?
Grifols (GRFS) has a market capitalization of $6.60B.
What is GRFS's P/E ratio?
Grifols trades at a price-to-earnings ratio of 9.0, with trailing twelve-month EPS of $0.87.
How fast is Grifols growing?
Grifols's revenue grew -0.2% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)